Kim A Margolin (Kim Margolin)

Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 9

Top Topics

Top Venues

Journal for immunotherapy of cancer

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Ari M VanderWalde, Shay L Bellasea, Kari L Kendra, Nikhil I Khushalani, Katie M Campbell, Philip O Scumpia, Lawrence F Kuklinski, Frances Collichio, Jeffrey A Sosman, Alexandra P Ikeguchi, Adrienne I Victor, Thach-Giao Truong, Bartosz Chmielowski, David C Portnoy, Yuanbin Chen, Kim A Margolin, Charles Bane, Constantin A Dasanu, Douglas B Johnson, Zeynep Eroglu, Sunandana Chandra, Egmidio Medina, Cynthia R Gonzalez, Ignacio Baselga-Carretero, Agustin Vega-Crespo, Ivan Perez Garcilazo, Elad Sharon, Siwen Hu-Lieskovan, Sapna Pradyuman Patel, Kenneth F Grossmann, James Moon, Michael C Wu, Antoni Ribas
Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial. Nature medicine (2023)
Kim A Margolin
The Dance Between Tumor Molecular Biology and Antitumor Immune Response. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H I Andtbacka
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. Journal for immunotherapy of cancer 10 (12) (2022)
Michael B Atkins, Hamzah Abu-Sbeih, Paolo Antonio Ascierto, Michael R Bishop, Daniel C Chen, Madhav Dhodapkar, Leisha A Emens, Marc S Ernstoff, Matthew J Ferris, Tim F Greten, James L Gulley, Roy S Herbst, Rachel W Humphrey, James Larkin, Kim A Margolin, Luca Mazzarella, Suresh S Ramalingam, Meredith M Regan, Brian I Rini, Mario Sznol
Maximizing the value of phase III trials in immuno-oncology: A checklist from the Society for Immunotherapy of Cancer (SITC). Journal for immunotherapy of cancer 10 (9) (2022)
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H I Andtbacka
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. Journal for immunotherapy of cancer 10 (12) (2022)
Alberto Mendoza-Valderrey, Maite Alvarez, Andrea De Maria, Kim A Margolin, Ignacio Melero, Maria Libera Ascierto
Next Generation Immuno-Oncology Strategies: Unleashing NK Cells Activity. Cells 11 (19) (2022)
Brendan D Curti, Jon Richards, John R Hyngstrom, Gregory A Daniels, Mark Faries, Lynn Feun, Kim A Margolin, Sigrun Hallmeyer, Mark Grose, Yiwei Zhang, Anlong Li, Robert H I Andtbacka
Intratumoral oncolytic virus V937 plus ipilimumab in patients with advanced melanoma: the phase 1b MITCI study. Journal for immunotherapy of cancer 10 (12) (2022)
Colt A Egelston, Christian Avalos, Travis Y Tu, Diana L Simons, Grecia Jimenez, Jae Y Jung, Laleh Melstrom, Kim A Margolin, John H Yim, Laura Kruper, Joanne Mortimer, Peter P Lee
Human breast tumor-infiltrating CD8+ T cells retain polyfunctionality despite PD-1 expression. Nature communications 9 (1) (2018)
Kim A Margolin
After a treatment breakthrough-progress, plateaus, and raising the bar. Cancer 123 (S11) (2018)